Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Invested Capital (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Invested Capital readings, the most recent being $605.7 million for Q1 2026.

  • On a quarterly basis, Invested Capital rose 32.39% to $605.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $605.7 million, a 32.39% increase, with the full-year FY2025 number at $567.6 million, up 29.46% from a year prior.
  • Invested Capital hit $605.7 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $567.6 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $605.7 million in Q1 2026 to a low of $153.5 million in Q2 2022.
  • Median Invested Capital over the past 5 years was $435.1 million (2024), compared with a mean of $420.5 million.
  • Biggest five-year swings in Invested Capital: tumbled 38.59% in 2022 and later skyrocketed 168.19% in 2023.
  • Kiniksa Pharmaceuticals International's Invested Capital stood at $396.1 million in 2022, then rose by 10.78% to $438.8 million in 2023, then fell by 0.09% to $438.4 million in 2024, then rose by 29.46% to $567.6 million in 2025, then grew by 6.71% to $605.7 million in 2026.
  • The last three reported values for Invested Capital were $605.7 million (Q1 2026), $567.6 million (Q4 2025), and $535.4 million (Q3 2025) per Business Quant data.